Ehren Rasmus, Habbig Sandra, Krupka Kai, Ernst Angela, Bald Martin, König Sabine, Murer Luisa, Özçakar Zeynep Birsin, Pohl Michael, Babenko Nadezhda, Spartà Giuseppina, Staude Hagen, Dello Strologo Luca, Szabó Attila J, Tönshoff Burkhard, Weber Lutz T
Pediatric Nephrology, Children's and Adolescents' Hospital, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Department of Pediatrics I, University Children's Hospital Heidelberg, Heidelberg, Germany.
Pediatr Transplant. 2022 Jun;26(4):e14265. doi: 10.1111/petr.14265. Epub 2022 Mar 9.
Asymptomatic hyperuricemia is frequently observed in pediatric kidney transplant recipients; symptomatic hyperuricemia, however, is a rare complication. Only few data are available in this patient population. We, therefore, investigated the prevalence of hyperuricemia and its association with kidney transplant function and blood pressure in a multicenter cohort of pediatric kidney transplant recipients.
This is a retrospective, observational multicenter registry study. All pediatric kidney transplant recipients in the CERTAIN database with at least one documented serum uric acid level and a follow-up of 5 years posttransplant were eligible. We identified 151 patients with 395 measurements of serum uric acid. We calculated the prevalence of hyperuricemia, analyzed potential risk factors and clinical consequences such as elevated blood pressure and reduced estimated glomerular filtration rate (eGFR). Statistical analysis was performed using IBM SPSS Statistics 26.
One hundred and ten of 395 (27.8%) serum uric acid levels were above 416 µmol/L (7.0 mg/dL), defined as the upper limit of normal. Univariate analysis showed a significant (p = .026) inverse association of serum uric acid with eGFR overtime. There was no significant association of serum uric acid concentrations with body mass index (z-score), blood pressure (z-score), or sex. No episodes of gout were documented.
This study shows that hyperuricemia is present in a considerable number of patients sometime after pediatric kidney transplantation and is associated with lower eGFR. Whether hyperuricemia contributes to faster decline of graft function or to the overall cardiovascular risk of these patients remains to be elucidated.
无症状高尿酸血症在小儿肾移植受者中较为常见;然而,有症状的高尿酸血症是一种罕见的并发症。关于这一患者群体的资料很少。因此,我们在一个多中心小儿肾移植受者队列中调查了高尿酸血症的患病率及其与肾移植功能和血压的关系。
这是一项回顾性观察性多中心注册研究。CERTAIN数据库中所有有至少一次记录的血清尿酸水平且移植后随访5年的小儿肾移植受者均符合条件。我们确定了151例患者,共进行了395次血清尿酸测量。我们计算了高尿酸血症的患病率,分析了潜在风险因素以及诸如血压升高和估计肾小球滤过率(eGFR)降低等临床后果。使用IBM SPSS Statistics 26进行统计分析。
395次血清尿酸测量中有110次(27.8%)高于416µmol/L(7.0mg/dL),这被定义为正常上限。单因素分析显示血清尿酸与eGFR随时间呈显著负相关(p = 0.026)。血清尿酸浓度与体重指数(z评分)、血压(z评分)或性别之间无显著关联。未记录到痛风发作。
本研究表明,相当一部分小儿肾移植患者在移植后的某个时间存在高尿酸血症,且与较低的eGFR相关。高尿酸血症是否会导致移植肾功能更快下降或增加这些患者的整体心血管风险仍有待阐明。